# A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib

> **NCT06378892** · PHASE2 · RECRUITING · sponsor: **Centro di Riferimento Oncologico - Aviano** · enrollment: 45 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer Metastatic
- ALK Gene Mutation

## Interventions

- **DRUG:** Lorlatinib

## Key facts

- **NCT ID:** NCT06378892
- **Lead sponsor:** Centro di Riferimento Oncologico - Aviano
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-15
- **Primary completion:** 2028-05
- **Final completion:** 2028-05
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2024-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06378892

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06378892, "A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06378892. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*